1947
Dr Alfredo Pavlovsky, a doctor in Buenos Aires, Argentina, distinguishes two types of haemophilia in his lab – A and B.1
Image courtesy of CSL Behring
1952
Image courtesy of CSL Behring
Stephen Christmas is diagnosed with haemophilia B, which doctors colloquially refer to as Christmas Disease. Fresh frozen plasma is the only treatment option available, and the average life expectancy is less than 20 years old.1
Image courtesy of CSL Behring
Stephen Christmas is diagnosed with haemophilia B, which doctors colloquially refer to as Christmas Disease. Fresh frozen plasma is the only treatment option available, and the average life expectancy is less than 20 years old.1
Patient
Dan has experienced the full treatment spectrum for haemophilia, from lyophilised plasma to factor. Now with a young grandson who also has haemophilia, he’s amazed by how far we’ve come and is excited for where the science is headed.
Dan's story
Image courtesy of Gary Bottoms
1970s
Image courtesy of Gary Bottoms
Factor concentrates in powdered form become available, allowing for home infusions and a significant reduction in treatment time.1
Researchers pioneer genetic engineering, creating the potential to treat genetic conditions by modifying a person’s genes.2
Image courtesy of Gary Bottoms
Factor concentrates in powdered form become available, allowing for home infusions and a significant reduction in treatment time.1
Researchers pioneer genetic engineering, creating the potential to treat genetic conditions by modifying a person’s genes.2
Healthcare Provider
Sue
Sue, a now-retired nurse coordinator, spent the last three decades on the front lines caring for people with haemophilia.
Sue's story
Image courtesy of Sue Geraghty
1980s
Image courtesy of Sue Geraghty
Scientists successfully clone the Factor VIII and IX genes, paving the way for breakthrough synthetic therapies (not derived from human plasma) using recombinant technologies.1
Image courtesy of Sue Geraghty
Scientists successfully clone the Factor VIII and IX genes, paving the way for breakthrough synthetic therapies (not derived from human plasma) using recombinant technologies.1
Image courtesy of Thomas Wilkes
1990s
Image courtesy of Thomas Wilkes
The first recombinant FIX products are approved by the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) to treat haemophilia B, leading the way for prophylactic treatment, which dramatically improves patients’ lives.1,3
Haemophilia patient life expectancy improves to 67 years old.4
Image courtesy of Thomas Wilkes
The first recombinant FIX products are approved by the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) to treat haemophilia B, leading the way for prophylactic treatment, which dramatically improves patients’ lives.1,3
Haemophilia patient life expectancy improves to 67 years old.4
Patient
Adam
A child of the 90s, Adam felt comfortable engaging in most activities with family and friends thanks to the availability of prophylactic haemophilia treatments.
Adam's Story
Healthcare Provider
Dr. Klamroth
A leader in the haemophilia medical community, Dr. Klamroth has witnessed several major treatment advancements over the past 25 years and looks forward to what the next 25 years will bring.
Dr. Klamroth’s Story
2000s
Evidence grows for the potential of adeno-associated virus (AAV) vectors to deliver safe, effective, and lasting genes that produce blood-clotting factor in the body.1
Evidence grows for the potential of adeno-associated virus (AAV) vectors to deliver safe, effective, and lasting genes that produce blood-clotting factor in the body.1
Patient
Jeron
Though held back from playing sports as a child, Jeron has channelled his energy into being an advocate in the haemophilia community, travelling the world and inspiring others with the condition.
Jeron's Story
Image courtesy of Jennifer Mermilliod
2010s
Image courtesy of Jennifer Mermilliod
Long-acting recombinant factor therapies are available offering the haemophilia community additional treatment options.1
Late-stage trials for AAV-based gene therapy in haemophilia begin.6
Image courtesy of Jennifer Mermilliod
Long-acting recombinant factor therapies are available offering the haemophilia community additional treatment options.1
Late-stage trials for AAV-based gene therapy in haemophilia begin.6
Patient/Caregiver
Stormy
As a woman with haemophilia and a caregiver to a son with haemophilia, Stormy has made it her mission to educate others, advocating for men and women alike in the haemophilia community.
Stormy's story
Image courtesy of Mike Hargett
2020s
Image courtesy of Mike Hargett
Gene therapy trials in haemophilia continue to show promise.8
Image courtesy of Mike Hargett
Gene therapy trials in haemophilia continue to show promise.8
Patient
Wayne
As an advocate for haemophilia for over 40 years, Wayne has experienced monumental advancements in haemophilia treatments and has committed his life to ensuring a better world for today’s haemophilia community.
Wayne's story
Patient
Lukas
Diagnosed at nine months old, Lukas hopes to shine a light on life with haemophilia, including the importance of increasing understanding of the disease to ensure children with haemophilia are given the same opportunities as their peers at school, as well as his hopes for the future.
Lukas' story